» Articles » PMID: 9140456

Cytogenetic Findings in 73 Osteosarcoma Specimens and a Review of the Literature

Overview
Date 1997 May 1
PMID 9140456
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-specific chromosomal abnormalities have been identified in several histologic subtypes of sarcomas. Characterization of recurrent chromosomal abnormalities has provided direction for molecular investigations of pathogenetically important genes. Cytogenetic reports of osteosarcoma, the most common primary malignant bone tumor, are relatively rare. In this study, 73 osteosarcoma specimens from 51 patients were cytogenetically analyzed following short-term culture. Clonal chromosomal abnormalities were detected in 47 and included one haploid specimen, 18 near-diploid specimens, 17 near-triploid, 8 near-tetraploid, 1 near-hexaploid, and 2 specimens with multiple clones of different ploidy levels. Examination of the present data and previously published data (111 clonally abnormal osteosarcoma specimens) reveals that chromosomal bands or regions 1p11-13, 1q10-12, 1q21-22, 11p15, 12p13, 17p12-13, 19q13, and 22q11-13 are most frequently rearranged and the most common numerical abnormalities are +1, -9, -10, -13, and -17. Partial or complete loss of the long arm of chromosome 6 also was seen in all cases of the present study and all previously published cases describing structural abnormalities of 6q. Parosteal osteosarcoma, a prognostically favorable osteosarcoma subtype, was characterized by the presence of a ring chromosome accompanied by no or few other abnormalities. Complex karyotypes were seen nearly exclusively in the high-grade lesions. These findings indicate that specific chromosomal bands and/or regions are nonrandomly involved in osteosarcoma and may provide useful clinical information.

Citing Articles

Comparative responses to demethylating therapy in animal models of osteosarcoma.

Huang S, Ren L, Beck J, Patkar S, Lillo Osuna M, Cherukuri A Res Sq. 2024; .

PMID: 38946977 PMC: 11213205. DOI: 10.21203/rs.3.rs-4451060/v1.


Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time.

Rajan S, Zaccaria S, Cannon M, Cam M, Gross A, Raphael B Cancer Res Commun. 2023; 3(4):564-575.

PMID: 37066022 PMC: 10093779. DOI: 10.1158/2767-9764.CRC-22-0348.


Clinical Targeted Next-Generation Panel Sequencing Reveals Amplification Is a Poor Prognostic Factor in Osteosarcoma.

Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A JCO Precis Oncol. 2023; 7:e2200334.

PMID: 36996377 PMC: 10531050. DOI: 10.1200/PO.22.00334.


Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.

Van Stiphout C, Luu A, Viloria-Petit A Cancers (Basel). 2022; 14(19).

PMID: 36230467 PMC: 9559645. DOI: 10.3390/cancers14194544.


Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma.

Taylor A, Sun J, Yu A, Voicu H, Shen J, Barkauskas D Int J Mol Sci. 2022; 23(14).

PMID: 35887382 PMC: 9319262. DOI: 10.3390/ijms23148036.